In findings that open the door to a completely different approach to curing HIV infections, scientists from the Florida campus of The Scripps Research Institute (TSRI) have for the first time shown that a novel compound effectively suppresses production of the virus in chronically infected cells, and prevents viral rebound, even when those infected cells are subjected to vigorous stimulation.
The study, led by TSRI Associate Professor Susana Valente, was published online Oct. 17 before print in the journal Cell Reports.
“No other anti-retroviral used in the clinic today is able to completely suppress viral production in infected cells in vivo,” Valente said. “When combining this drug with the standard cocktail of anti-retrovirals used to suppress infection in humanized mouse models of HIV-1 infection, our study found a drastic reduction in virus RNA present—it is really the proof-of-concept for a ‘functional cure.’”
Valente, a pioneer in this new approach, calls it “Block-and-Lock”—the approach blocks reactivation of the virus in cells, even during treatment interruptions, and locks HIV into durable state of latency.
Valente and her colleagues use a derivative of a natural compound called didehydro-Cortistatin A (dCA), which blocks replication in HIV-infected cells by inhibiting the viral transcriptional activator, called Tat, halting viral production, reactivation and replenishment of the latent viral reservoir.
“Combining dCA with anti-retroviral therapy accelerates HIV-1 suppression and prevents viral rebound after treatment interruption, even during strong cellular activation,” Valente said. “It’s important to note that our study uses the maximum tolerable dose of the drug—with virtually no side effects.”
The scientists studied the combination therapy in a mouse model of HIV latency and persistence. Once the combined treatment regimen was halted, viral rebound was delayed up to 19 days, compared with just seven days in mouse models receiving only anti-retroviral treatment.
“This demonstrates the potential of ‘block-and-lock’ strategies,” said TSRI Research Associate Cari F. Kessing, co-first author of the study. “This study shows that a ‘functional cure’ approach can succeed in reducing residual virus in the blood during anti-retroviral treatment and limiting viral rebound during treatment interruption.”
“In half of the dCA treated mice, the virus was undetectable for 16 days after all treatment was halted,” said the University of North Carolina’s Christopher Nixon, another first author.
“We blocked Tat, and the cell’s machinery did the rest,” said TSRI Research Associate Chuan Li, a coauthor of the study. “The result was that the HIV promoter becomes repressed.”
Valente pointed out that the animal models were exposed to just a single month of treatment. “That’s a relatively short period of time,” she said. “We think longer treatments will result in longer, or even permanent, rebound delays. The question is how long? We’re studying that now.”
Because any viral rebound of HIV comes with a host of adverse effects, Valente noted, blocking that rebound would automatically reduce those effects.
“This is the only class of drugs that stops infected cells from making viruses outright,” said Valente. “All current antivirals work later in the viral lifecycle, so only a HIV transcriptional inhibitor like dCA can stop the side effects of low-level virus production.”
The Latest on: HIV
- Federal, local officials aim to cut HIV infections in Austin and U.S.on July 16, 2019 at 8:06 pm
U.S. Centers for Disease Control and Prevention Director Robert Redfield said he remembers a time 30 years ago when people with HIV had to take 40 pills a day just to hope to live 26 more months. ... […]
- The HIV epidemic continues to devastate Alabama. We need the ACAon July 16, 2019 at 4:07 pm
I was diagnosed with HIV in 2000. Doctors didn’t give me very long to live. As a result, I immediately qualified for Supplemental Security Income (SSI). This made me eligible for Medicare, which was a ... […]
- Planned Parenthood Arizona receives $10K from Phoenix Pride for HIV preventionon July 16, 2019 at 2:54 pm
Planned Parenthood Arizona receives $10K from Phoenix Pride for HIV prevention Planned Parenthood Arizona is teaming up with Aunt Rita's Foundation in Phoenix to reach patients who seek preventative ... […]
- HIV-infected cells persist in CSF in individuals on long-term ARTon July 16, 2019 at 11:26 am
(HealthDay)—About half of HIV-positive individuals on long-term antiretroviral therapy (ART) have HIV-infected cells in their cerebrospinal fluid (CSF), according to a study published online ... […]
- HIV lurking in spinal fluid linked to thinking problemson July 16, 2019 at 11:16 am
TUESDAY, July 16, 2019—(HealthDay News) Even with long-term treatment, HIV can still be found in the cerebrospinal fluid of some people with the AIDS-causing virus, a new study reports. ... […]
- GSK's Two-Drug HIV Dovato Treatment Meets Main Goal in Studyon July 16, 2019 at 9:57 am
(Reuters) - GlaxoSmithKline Plc's two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a ... […]
- HIV in spinal fluid linked to thinking problemson July 16, 2019 at 8:59 am
Even with long-term treatment, HIV can still be found in the cerebrospinal fluid of some people with the AIDS-causing virus, a new study reports. And these patients are at increased risk of having ... […]
- HIV/AIDS deaths fall by one-third since 2010, but experts say more could be doneon July 16, 2019 at 7:07 am
The number of deaths attributed to the AIDS virus has declined by one-third worldwide since 2010, according to a new report by UNAIDS, a joint United Nations program. There were 770,000 AIDS-related ... […]
- Restriction of HIV-1 and other retroviruses by TRIM5on July 16, 2019 at 5:21 am
Mammalian cells express a variety of innate immune proteins — known as restriction factors — which defend against invading retroviruses such as HIV-1. Two members of the tripartite motif protein ... […]
- Mixed results on UN’s annual report on HIV/AIDS calls for urgent increase in political leadershipon July 16, 2019 at 4:29 am
In its annual report on HIV/AIDS, the United Nations found both hopeful and troubling signs in the global fight to end the epidemic, according to a report released Tuesday. But overall, the pace of ... […]
via Google News and Bing News